<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04342442</url>
  </required_header>
  <id_info>
    <org_study_id>KIN-SR-GvHD</org_study_id>
    <nct_id>NCT04342442</nct_id>
  </id_info>
  <brief_title>Identification of Novel Targetable Kinases in SR-a GvHD</brief_title>
  <official_title>Investigation of Novel Targetable Kinases in Steroid-refractory Acute Graft-versus-host Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Freiburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Freiburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigators aim to identify novel targetable kinases in SR-a GvHD
      patient samples and investigate their role in different immune cell subtypes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Corticosteroids are the first-line treatment of a GvHD, however many patients do not respond
      to corticosteroids. Patients with steroid-refractory a GvHD (SR-a GVHD) have a low 1-year
      survival rate. In this study, the investigators aim to identify and validate novel targetable
      kinases in SR-a GvHD patient peripheral blood mononuclear cells (PBMCs) by using a
      kinase-specific proteomic approach, and thereafter to investigate the role of the identified
      kinases in different immune cell subtypes by analyzing biopsies taken from SR- a GvHD
      patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of differentially regulated kinases</measure>
    <time_frame>3 years</time_frame>
    <description>Bead-based Kinase Assay enrichment (Knet beads) of PBMC lysates</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analysis of protein expression</measure>
    <time_frame>3 years</time_frame>
    <description>Analysis of PBMC lysates by western blot</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of immune cell subtype</measure>
    <time_frame>3 years</time_frame>
    <description>Immunohistochemistry of intestinal biopsies</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">24</enrollment>
  <condition>Graft Versus Host Disease</condition>
  <arm_group>
    <arm_group_label>Steroid-refractory a GvHD</arm_group_label>
    <description>Analysis of peripheral blood and intestinal biopsies of patients suffering from steroid-refractory a GvHD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Steroid-responsive a GvHD</arm_group_label>
    <description>Analysis of peripheral blood and intestinal biopsies of patients suffering from steroid-responsive a GvHD</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with acute GvHD, steroid-refractory or steroid-responsive
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  allo-transplanted

          -  confirmed diagnosis of a GvHD

          -  age ≥ 18 years

          -  peripheral blood samples and biopsies available

          -  written informed consent

          -  ability to understand the nature of the study and the study-related procedures and to
             comply with them

        Exclusion Criteria:

          -  age &lt; 18 years

          -  lack of informed consent

          -  patients that cannot be classified in one of the 2 groups (steroid-refractory,
             steroid-responsive)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Zeiser, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Freiburg</affiliation>
  </overall_official>
  <reference>
    <citation>Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, Spoerl S, Ditschkowski M, Ecsedi M, Sockel K, Ayuk F, Ajib S, de Fontbrune FS, Na IK, Penter L, Holtick U, Wolf D, Schuler E, Meyer E, Apostolova P, Bertz H, Marks R, Lübbert M, Wäsch R, Scheid C, Stölzel F, Ordemann R, Bug G, Kobbe G, Negrin R, Brune M, Spyridonidis A, Schmitt-Gräff A, van der Velden W, Huls G, Mielke S, Grigoleit GU, Kuball J, Flynn R, Ihorst G, Du J, Blazar BR, Arnold R, Kröger N, Passweg J, Halter J, Socié G, Beelen D, Peschel C, Neubauer A, Finke J, Duyster J, von Bubnoff N. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015 Oct;29(10):2062-8. doi: 10.1038/leu.2015.212. Epub 2015 Jul 31.</citation>
    <PMID>26228813</PMID>
  </reference>
  <reference>
    <citation>Hülsdünker J, Ottmüller KJ, Neeff HP, Koyama M, Gao Z, Thomas OS, Follo M, Al-Ahmad A, Prinz G, Duquesne S, Dierbach H, Kirschnek S, Lämmermann T, Blaser MJ, Fife BT, Blazar BR, Beilhack A, Hill GR, Häcker G, Zeiser R. Neutrophils provide cellular communication between ileum and mesenteric lymph nodes at graft-versus-host disease onset. Blood. 2018 Apr 19;131(16):1858-1869. doi: 10.1182/blood-2017-10-812891. Epub 2018 Feb 20.</citation>
    <PMID>29463561</PMID>
  </reference>
  <reference>
    <citation>Zeiser R, Blazar BR. Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy. N Engl J Med. 2017 Nov 30;377(22):2167-2179. doi: 10.1056/NEJMra1609337. Review.</citation>
    <PMID>29171820</PMID>
  </reference>
  <reference>
    <citation>Schwab L, Goroncy L, Palaniyandi S, Gautam S, Triantafyllopoulou A, Mocsai A, Reichardt W, Karlsson FJ, Radhakrishnan SV, Hanke K, Schmitt-Graeff A, Freudenberg M, von Loewenich FD, Wolf P, Leonhardt F, Baxan N, Pfeifer D, Schmah O, Schönle A, Martin SF, Mertelsmann R, Duyster J, Finke J, Prinz M, Henneke P, Häcker H, Hildebrandt GC, Häcker G, Zeiser R. Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage. Nat Med. 2014 Jun;20(6):648-54. doi: 10.1038/nm.3517. Epub 2014 May 18.</citation>
    <PMID>24836575</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 8, 2020</study_first_submitted>
  <study_first_submitted_qc>April 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2020</study_first_posted>
  <last_update_submitted>April 8, 2020</last_update_submitted>
  <last_update_submitted_qc>April 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Freiburg</investigator_affiliation>
    <investigator_full_name>Robert Zeiser</investigator_full_name>
    <investigator_title>Director of Division of Tumor Immunology</investigator_title>
  </responsible_party>
  <keyword>Steroid-refractory GvHD</keyword>
  <keyword>Myeloid cells</keyword>
  <keyword>Allogeneic hematopoietic cell transplantation (allo-HCT)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

